<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01762345</url>
  </required_header>
  <id_info>
    <org_study_id>2012099</org_study_id>
    <nct_id>NCT01762345</nct_id>
  </id_info>
  <brief_title>A Pilot Clinical Study of the Efficacy and Safety of a Disposable Intravaginal Device for Stress Urinary Incontinence</brief_title>
  <official_title>A Pilot Clinical Study of the Efficacy and Safety of a Disposable Intravaginal Device for Stress Urinary Incontinence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Procter and Gamble</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Procter and Gamble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study will evaluate the efficacy of the pessary (disposable intra-vaginal device)
      by reduction in urine leakage in women with stress urinary incontinence (SUI).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Pad Weight Gain</measure>
    <time_frame>from the 14-day baseline period to the last 7 days of 14-day device usage period</time_frame>
    <description>Change from baseline as measured as reduction (improvement) in pad weight gain. Positive values are indicative of efficacious outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Stress Urinary Incontinence Episodes</measure>
    <time_frame>from the 14-day baseline period to the last 7 days of 14-day device usage period</time_frame>
    <description>Change from baseline as measured as reduction (improvement) in stress urinary incontinence episodes. Positive values are indicative of efficacious outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Pad Weight Gain</measure>
    <time_frame>from the 14-day baseline period to the first 7 days of 14-day device usage period</time_frame>
    <description>Change from baseline as measured as reduction (improvement) in pad weight gain. Positive values are indicative of efficacious outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Stress Urinary Incontinence Episodes</measure>
    <time_frame>from the 14-day baseline period to the first 7 days of 14-day device usage period</time_frame>
    <description>Change from baseline as measured as reduction (improvement) in stress urinary incontinence episodes. Positive values are indicative of efficacious outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life as Measured by Incontinence Impact Questionnaire (IIQ-7)</measure>
    <time_frame>baseline and end-of-treatment</time_frame>
    <description>The IIQ-7 is based on 7 questions referring to areas which may have been influenced or changed by accidental urine loss and/or prolapse. These questions are assigned a value of, 0 = 'Not at all,' 1= 'Slightly,' 2 = 'Moderately,' or 3 'Greatly.' The IIQ-7 is scored by taking the average score of items and then multiplying the average by 33 1/3 to put scores on a scale from 0 to 100. A lower score is considered less impact to quality of life and a higher score reflects more impact to quality of life. In the same manner, a reduction in scores from baseline reflects improved quality of life.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Percentage of Responders for Pad Weight Gain</measure>
    <time_frame>from the 14-day baseline period to the last 7 days of 14-day device usage period</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Responders for SUI Episodes</measure>
    <time_frame>from the 14-day baseline period to the last 7 days of 14-day device usage period</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">148</enrollment>
  <condition>Stress Urinary Incontinence</condition>
  <arm_group>
    <arm_group_label>pessary device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pessary (disposable intra-vaginal device)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>pessary (disposable intra-vaginal device)</intervention_name>
    <description>pessary device(disposable intra-vaginal device)manufactured by Procter &amp; Gamble</description>
    <arm_group_label>pessary device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  have a ≥ 3 month history of experiencing Stress Urinary Incontinence

          -  be willing to use the pessary investigational device to control stress incontinence

        Exclusion Criteria:

          -  pregnant, lactating or planning to become pregnant during the study

          -  within 3 months post partum

          -  intrauterine device (IUD) placement of less than 6 months

          -  a history of Toxic Shock Syndrome (TSS) or symptoms consistent with TSS

          -  experience difficulty inserting or wearing an intra-vaginal device, including a tampon

          -  vaginal surgery, perineal surgery, uterine surgery, or abortion (spontaneous or
             induced) within the past 3 months

          -  has any Screening laboratory value outside the laboratory reference range considered
             clinically significant by the Investigator

          -  for any reason, the Investigator decides that the subject should not participate in
             the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Randall Severance, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radiant Research, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Study Center</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2012</study_first_submitted>
  <study_first_submitted_qc>January 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2013</study_first_posted>
  <results_first_submitted>January 15, 2016</results_first_submitted>
  <results_first_submitted_qc>February 23, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 24, 2016</results_first_posted>
  <last_update_submitted>February 23, 2016</last_update_submitted>
  <last_update_submitted_qc>February 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stress urinary incontinence</keyword>
  <keyword>SUI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Incontinence, Stress</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>148 subjects entered the 2-week baseline phase and 65 dropped/failed before treatment</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Pessary Device</title>
          <description>pessary (disposable intra-vaginal device)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="83"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pessary Device</title>
          <description>pessary (disposable intra-vaginal device)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="83"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.7" spread="9.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Pad Weight Gain</title>
        <description>Change from baseline as measured as reduction (improvement) in pad weight gain. Positive values are indicative of efficacious outcome.</description>
        <time_frame>from the 14-day baseline period to the last 7 days of 14-day device usage period</time_frame>
        <population>Intent-to-Treat (ITT) population. The &quot;Number of Participants Analyzed&quot; is the number subjects with available (non-missing) data in week 2</population>
        <group_list>
          <group group_id="O1">
            <title>Pessary Device</title>
            <description>pessary (disposable intra-vaginal device)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pad Weight Gain</title>
          <description>Change from baseline as measured as reduction (improvement) in pad weight gain. Positive values are indicative of efficacious outcome.</description>
          <population>Intent-to-Treat (ITT) population. The &quot;Number of Participants Analyzed&quot; is the number subjects with available (non-missing) data in week 2</population>
          <units>grams/usage period</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.67" lower_limit="0.12" upper_limit="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Stress Urinary Incontinence Episodes</title>
        <description>Change from baseline as measured as reduction (improvement) in stress urinary incontinence episodes. Positive values are indicative of efficacious outcome.</description>
        <time_frame>from the 14-day baseline period to the last 7 days of 14-day device usage period</time_frame>
        <population>Intent-to-Treat (ITT) population. The &quot;Number of Participants Analyzed&quot; is the number subjects with available (non-missing) data in week 2</population>
        <group_list>
          <group group_id="O1">
            <title>Pessary Device</title>
            <description>pessary (disposable intra-vaginal device)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Stress Urinary Incontinence Episodes</title>
          <description>Change from baseline as measured as reduction (improvement) in stress urinary incontinence episodes. Positive values are indicative of efficacious outcome.</description>
          <population>Intent-to-Treat (ITT) population. The &quot;Number of Participants Analyzed&quot; is the number subjects with available (non-missing) data in week 2</population>
          <units>episodes/usage period</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.92" lower_limit="0.22" upper_limit="1.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Pad Weight Gain</title>
        <description>Change from baseline as measured as reduction (improvement) in pad weight gain. Positive values are indicative of efficacious outcome.</description>
        <time_frame>from the 14-day baseline period to the first 7 days of 14-day device usage period</time_frame>
        <population>Intent-to-Treat (ITT) population. The &quot;Number of Participants Analyzed&quot; is the number subjects with available (non-missing) data in week 1</population>
        <group_list>
          <group group_id="O1">
            <title>Pessary Device</title>
            <description>pessary (disposable intra-vaginal device)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pad Weight Gain</title>
          <description>Change from baseline as measured as reduction (improvement) in pad weight gain. Positive values are indicative of efficacious outcome.</description>
          <population>Intent-to-Treat (ITT) population. The &quot;Number of Participants Analyzed&quot; is the number subjects with available (non-missing) data in week 1</population>
          <units>grams/usage period</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.36" lower_limit="0.16" upper_limit="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Stress Urinary Incontinence Episodes</title>
        <description>Change from baseline as measured as reduction (improvement) in stress urinary incontinence episodes. Positive values are indicative of efficacious outcome.</description>
        <time_frame>from the 14-day baseline period to the first 7 days of 14-day device usage period</time_frame>
        <population>Intent-to-Treat (ITT) population. The &quot;Number of Participants Analyzed&quot; is the number subjects with available (non-missing) data in week 1</population>
        <group_list>
          <group group_id="O1">
            <title>Pessary Device</title>
            <description>pessary (disposable intra-vaginal device)
pessary (disposable intra-vaginal device): pessary device(disposable intra-vaginal device)manufactured by Procter &amp; Gamble</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Stress Urinary Incontinence Episodes</title>
          <description>Change from baseline as measured as reduction (improvement) in stress urinary incontinence episodes. Positive values are indicative of efficacious outcome.</description>
          <population>Intent-to-Treat (ITT) population. The &quot;Number of Participants Analyzed&quot; is the number subjects with available (non-missing) data in week 1</population>
          <units>episodes/usage period</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.65" lower_limit="0.17" upper_limit="1.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quality of Life as Measured by Incontinence Impact Questionnaire (IIQ-7)</title>
        <description>The IIQ-7 is based on 7 questions referring to areas which may have been influenced or changed by accidental urine loss and/or prolapse. These questions are assigned a value of, 0 = ‘Not at all,’ 1= ‘Slightly,’ 2 = ‘Moderately,’ or 3 ‘Greatly.’ The IIQ-7 is scored by taking the average score of items and then multiplying the average by 33 1/3 to put scores on a scale from 0 to 100. A lower score is considered less impact to quality of life and a higher score reflects more impact to quality of life. In the same manner, a reduction in scores from baseline reflects improved quality of life.</description>
        <time_frame>baseline and end-of-treatment</time_frame>
        <population>Intent-to-Treat (ITT) population. The &quot;Number of Participants Analyzed&quot; is the number subjects with available (non-missing) data at the end of treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Pessary Device</title>
            <description>pessary (disposable intra-vaginal device)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quality of Life as Measured by Incontinence Impact Questionnaire (IIQ-7)</title>
          <description>The IIQ-7 is based on 7 questions referring to areas which may have been influenced or changed by accidental urine loss and/or prolapse. These questions are assigned a value of, 0 = ‘Not at all,’ 1= ‘Slightly,’ 2 = ‘Moderately,’ or 3 ‘Greatly.’ The IIQ-7 is scored by taking the average score of items and then multiplying the average by 33 1/3 to put scores on a scale from 0 to 100. A lower score is considered less impact to quality of life and a higher score reflects more impact to quality of life. In the same manner, a reduction in scores from baseline reflects improved quality of life.</description>
          <population>Intent-to-Treat (ITT) population. The &quot;Number of Participants Analyzed&quot; is the number subjects with available (non-missing) data at the end of treatment</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.52" lower_limit="0" upper_limit="28.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Responders for Pad Weight Gain</title>
        <time_frame>from the 14-day baseline period to the last 7 days of 14-day device usage period</time_frame>
        <population>Intent-to-Treat (ITT) population. The &quot;Number of Participants Analyzed&quot; is the number subjects with available (non-missing) data in week 2</population>
        <group_list>
          <group group_id="O1">
            <title>Pessary Device</title>
            <description>pessary (disposable intra-vaginal device)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Responders for Pad Weight Gain</title>
          <population>Intent-to-Treat (ITT) population. The &quot;Number of Participants Analyzed&quot; is the number subjects with available (non-missing) data in week 2</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Responders for SUI Episodes</title>
        <time_frame>from the 14-day baseline period to the last 7 days of 14-day device usage period</time_frame>
        <population>Intent-to-Treat (ITT) population. The &quot;Number of Participants Analyzed&quot; is the number subjects with available (non-missing) data in week 2</population>
        <group_list>
          <group group_id="O1">
            <title>Pessary Device</title>
            <description>pessary (disposable intra-vaginal device)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Responders for SUI Episodes</title>
          <population>Intent-to-Treat (ITT) population. The &quot;Number of Participants Analyzed&quot; is the number subjects with available (non-missing) data in week 2</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 weeks</time_frame>
      <desc>All adverse events reported by the subject from study initiation [Visit 1 (Screening)] until study completion [Visit 3 (End-of-Treatment)] were recorded.</desc>
      <group_list>
        <group group_id="E1">
          <title>Pessary Device</title>
          <description>pessary (disposable intra-vaginal device)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>urinary tract infection (UTI)</sub_title>
                <description>UTI</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>vaginal hemorrhage</sub_title>
                <description>vaginal bleeding</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>vaginal discomfort</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The STUDY SITE and PRINCIPAL INVESTIGATOR agree that all data, calculations, interpretations, opinions and recommendations regarding the STUDY (hereinafter referred to as
“RESULTS”) shall be the property of P&amp;G. The STUDY SITE and PRINCIPAL INVESTIGATOR agree to consider the RESULTS as INFORMATION subject to confidentiality restrictions</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mylissa Trowbridge</name_or_title>
      <organization>Procter &amp; Gamble Company Global Clinical Sciences</organization>
      <email>trowbridge.mm@pg.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

